Free tool
FAERS Monitor: Vraylar
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 204370 or its brand name (Vraylar, Cariprazine Hydrochloride). Reports on generic versions are filed under their own applications.
Reports
9,636
Serious
3,459
36% of reports
Hospitalization
1,349
Death reported
258
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- off label use1,083
- drug ineffective566
- weight increased501
- akathisia434
- anxiety392
- tardive dyskinesia392
- tremor378
- nausea373
- fatigue368
- insomnia354
- suicidal ideation337
- depression296
- dizziness290
- somnolence253
- feeling abnormal231
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2011 | 2 |
| 2015 | 1 |
| 2016 | 156 |
| 2017 | 337 |
| 2018 | 415 |
| 2019 | 890 |
| 2020 | 1,030 |
| 2021 | 853 |
| 2022 | 850 |
| 2023 | 1,259 |
| 2024 | 1,294 |
| 2025 | 1,516 |
| 2026 | 1,033 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,044,523 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| akathisiaSignal | 434 | 71.7 | 65.3 | 29,232 |
| tardive dyskinesiaSignal | 392 | 30.7 | 27.9 | 11,109 |
| suicidal ideationSignal | 337 | 8.1 | 7.3 | 2,079 |
| tremorSignal | 378 | 5.0 | 4.5 | 1,205 |
| weight increasedSignal | 501 | 4.9 | 4.5 | 1,561 |
| anxietySignal | 392 | 3.0 | 2.7 | 530 |
| insomniaSignal | 354 | 2.9 | 2.6 | 445 |
| depressionSignal | 296 | 2.8 | 2.5 | 355 |
| somnolenceSignal | 253 | 2.7 | 2.4 | 281 |
| off label useSignal | 1,083 | 2.7 | 2.6 | 1,208 |
| feeling abnormalSignal | 231 | 2.1 | 1.9 | 134 |
| dizziness | 290 | 1.3 | 1.1 | 17 |
| fatigue | 368 | 1.0 | 0.9 | 0 |
| nausea | 373 | 1.0 | 0.9 | 0 |
| drug ineffective | 566 | 0.9 | 0.9 | 2 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.